Moderna stock trades below its 52-week high before cancer data

Moderna stock was trading at USD 182.11 on Nasdaq on September 23, 2026, 5.3 percent below its 52-week high of USD 192.31. The company is now approaching a major oncology data date as its latest quarterly revenue exceeded consensus.

Melanoma data set for October

According to Moderna, Phase 3 data for intismeran autogene in resected stage IIB-IV melanoma were selected for a Presidential Symposium at the ESMO Congress on October 24, 2026.

The company also scheduled an investor webcast for October 24, 2026, at 1:00 p.m. EDT. Three ESMO abstracts will cover melanoma as well as updates involving the personalized therapy in pancreatic and lung cancer, giving the oncology pipeline several near-term evidence points.

Revenue beats estimates while losses continue

In Q2 2026, Moderna generated USD 145.00 million in revenue versus USD 102.93 million consensus, a 40.9 percent difference. Revenue also increased 2.1 percent from the same quarter a year earlier, according to MarketBeat.

Quarterly EPS was USD -1.97 against a USD -2.03 consensus estimate, a USD 0.06 beat. The result remains loss-making, but the revenue gap shows that commercial performance and pipeline valuation are pulling in different directions.

Analyst target trails the quote

The valuation debate is unusually wide. MarketBeat reports a Hold consensus and an average price target of USD 76.72, while Moderna's latest Nasdaq quote stood at USD 182.11 on September 23, 2026. The target is 57.9 percent below that quote, leaving the October data presentation as the next measurable test for the oncology narrative.

Stock remains below yearly high

Moderna's market capitalization was USD 72,258,698,460 on September 23, 2026. The Nasdaq quote of USD 182.11 was above the session's prior close of USD 182.56 and sat within the 52-week range of USD 22.28 to USD 192.31.